+86 27 8798 8585
| |

Latest News

You are at the location of:Home - Latest News - Industry News

Pfizers Trumenba gets breakthrough status for meningococcal disease

Article source:Station editor Update time:2018-05-03 16:17:16   Browsing times:second

The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Pfizers Trumenba for meningococcal B disease in children aged between one and nine.

Trumenba is being formulated as a vaccine to provide active immunisation to prevent meningococcal B. The disease is caused by Neisseria meningitidis group B (MenB), known to primarily affect adolescents and young adults in the US and Europe.
In 2014, the drug candidate received breakthrough status for use in adolescents and young adults aged 10 to 25, and secured full approval in 2017 as a three-dose schedule.